cyproheptadine has been researched along with lorazepam in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Strassburg, CP; Tukey, RH | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Clarke, A; File, SE | 1 |
| Antonijoan, RM; Ballester, MR; Barbanoj, MJ; Donado, E; García-Gea, C; Izquierdo, I; Martínez, J | 1 |
| Hardman, MI; Sprung, J; Weingarten, TN | 1 |
| Basta, MN | 1 |
5 review(s) available for cyproheptadine and lorazepam
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.
Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor Antagonists; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; Haloperidol; Humans; Lorazepam; Male; Melatonin; Neuroleptic Malignant Syndrome; Olanzapine; Receptors, GABA; Substance Withdrawal Syndrome; Substance-Related Disorders; Young Adult | 2019 |
Postoperative Serotonin Syndrome Following Methylene Blue Administration for Vasoplegia After Cardiac Surgery: A Case Report and Review of the Literature.
Topics: Cardiac Surgical Procedures; Cyproheptadine; Enzyme Inhibitors; Humans; Hypnotics and Sedatives; Lorazepam; Male; Methylene Blue; Middle Aged; Neuromuscular Nondepolarizing Agents; Postoperative Complications; Rocuronium; Serotonin Antagonists; Serotonin Syndrome; Vasoplegia | 2021 |
1 trial(s) available for cyproheptadine and lorazepam
| Article | Year |
|---|---|
Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study.
Topics: Adult; Central Nervous System Depressants; Cross-Over Studies; Cyproheptadine; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Histamine H1 Antagonists; Humans; Lorazepam; Male; Psychomotor Performance | 2010 |
2 other study(ies) available for cyproheptadine and lorazepam
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
Effects of ACTH, benzodiazepines and 5-HT antagonists on escape from periaqueductal grey stimulation in the rat.
Topics: Adrenocorticotropic Hormone; Animals; Anti-Anxiety Agents; Avoidance Learning; Cerebral Aqueduct; Chlordiazepoxide; Cyproheptadine; Electric Stimulation; Escape Reaction; Hydroxyindoleacetic Acid; Lorazepam; Male; Methysergide; Muridae; Reaction Time; Receptors, Serotonin; Serotonin; Serotonin Antagonists | 1982 |